Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease

• Published in: Brain sciences Vol. 14; no. 8; p. 776
• Main Authors: Crispo, James A G, Farhat, Nawal, Fortin, Yannick, Perez-Lloret, Santiago, Sikora, Lindsey, Morgan, Rebecca L, Habash, Mara, Gogna, Priyanka, Kelly, Shannon E, Elliott, Jesse, Kohen, Dafna E, Bjerre, Lise M, Mattison, Donald R, Hessian, Renée C, Willis, Allison W, Krewski, Daniel
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 31.07.2024; MDPI
• Subjects: Agonists; Bias; Bromocriptine; Canada; Cardiac glycosides; Cardiac patients; Cardiotonic agents; Cardiovascular disease; Cardiovascular diseases; cardiovascular reactions; Clinical trials; Comparative analysis; Complications and side effects; Congestive heart failure; Diseases; Dopamine; Drug dosages; Edema; Enzymes; Ergot; Heart diseases; Heart failure; Intervention; medication safety; Movement disorders; Neurodegenerative diseases; non-ergot dopamine agonists; Online databases; Ontario; Orthostatic hypotension; Parkinson's disease; Phenols; Restless legs syndrome; Risk factors; Ropinirole; Systematic Review; Canada; Ontario; United States > US; heart failure; non-ergot dopamine agonists; medication safety; meta-analysis; non-randomized studies; cardiovascular reactions; randomized controlled trials; systematic review; Parkinson’s disease

Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD...